Ossur Americas, Inc.
$259.2K 1,080 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ClearFlow Inc.
ClearFlow Inc. reported $259,252.48 across General Payments, Research, and Ownership to 51 physicians and teaching hospitals across 52 transactions.
- $259.3K Above-median payer
- All-tracks total
- 52 Below-median volume
- Transactions
- 51 Below-median reach
- Recipients
- −$39.8K
- General Payments vs PY2023
ClearFlow Inc. reported $259,252.48 across all CMS Open Payments tracks (General + Research + Ownership) to 51 physicians and teaching hospitals in Program Year 2024 - ranking #924 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $112,536.04, averaging $5.1K per recipient.
How ClearFlow Inc.'s $259.3K all-tracks total breaks down
ClearFlow Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
12/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer clearflow-inc ClearFlow Inc.
$259.3K · #924/1,925 · 0.0% industry · PY2024
- TOT $259.3K
- RANK #924
- SHARE 0.0%
- TXN 52
- RCP 51
- CAT 2
- GEN $112.5K
- ΔGEN −$39.8K
- TOP1 57.8%
- PY 2024
Volume peers
Nearest volume peer: Ossur Americas, Inc. ($259.2K)
ClearFlow Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ClearFlow Inc.'s CMS-reported General Payments decreased by $39.8K (−26.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CLEARFLOW INC.PY2023: CLEARFLOW INC.PY2024: ClearFlow Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $152,309.39
- PY2024
- $112,536.04
What the Data Shows for ClearFlow Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For ClearFlow Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
25 transactions worth $110.5K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 98.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
ClearFlow Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $110.5K, 98.2% of General Payments.
How ClearFlow Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $110.5K | 25 | 98.2% |
| Food and Beverage | $2.0K | 26 | 1.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $111,074.20 (98.7%) of $112,536.04 in this company's General Payments records across 23 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ClearFlow Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Alan Gillinov
$65,000.00 across 12 reported transactions
- 2
Marc Gerdisch
$45,500.00 across 13 reported transactions
- 3
Peter Rodgers-Fischl
$191.40 across 2 reported transactions
- 4
Michael Ritchie
$191.40 across 2 reported transactions
- 5
Hazaim Alwair
$191.40 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ClearFlow Inc. ranks #924 of 1,925 by total payments (top 48% by spend) but is notably more concentrated than that alone would suggest -- #371 of 1,838 by HHI (top 20% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Astellas Pharma Europe BV : $143.10 total payments, HHI 5000
- Mobius Therapeutics, LLC : $1.0K total payments, HHI 5000
- SmartPractice Allergen Bank, L.L.C. : $1.4M total payments, HHI 5000
- LumiraDx, Inc. : $600.00 total payments, HHI 5000
- STORZ MEDICAL America, Inc. : $55.30 total payments, HHI 5000
- OTU Medical Inc. : $20.0K total payments, HHI 5000
- ClearFlow Inc. (this company) : $112.5K total payments, HHI 4971
- 3D Systems : $2.5K total payments, HHI 4970
- Encision Inc : $7.1K total payments, HHI 4966
- ExThera Medical Corporation : $192.6K total payments, HHI 4943
- Itamar Medical Inc : $477.1K total payments, HHI 4917
- Elekta Limited : $1.3K total payments, HHI 4913
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ClearFlow Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ClearFlow Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ClearFlow Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Urgo Medical North America, LLC
$258.8K 3,944 recipients
Compare payment profiles
Surgical Information Sciences, Inc.
$258.3K 6 recipients
Compare payment profiles
IQ Med LLC
$260.2K 0 recipients
Compare payment profiles
Ascensia Diabetes Care Us Inc.
$258.2K 3,812 recipients
Compare payment profiles
ETS Wound Care LLC
$260.4K 942 recipients
Compare payment profiles
Put this to use
ClearFlow Inc. ranks #924 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just ClearFlow Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.